Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-10
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2021-03-31 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-03-31 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-10 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-10 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-03-13 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-13 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-08 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-09 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-11 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-20 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-13 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-03-13 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-14 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-16 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |